Oxis Turbuhaler

Oxis Turbuhaler is a pharmaceutical product primarily used for the management of respiratory conditions such as asthma and COPD. The active ingredient, formoterol fumarate dihydrate, is delivered through the patented Turbuhaler device, which was originally developed in Sweden by Astra AB.

Following the merger of Astra AB and Zeneca Group PLC in 1999, the brand is owned by AstraZeneca. While the brand has strong Swedish roots, the manufacturing of the Turbuhaler devices and the filling of the medication are conducted at high-tech pharmaceutical facilities globally, with a significant production hub located in Dunkerque, France. AstraZeneca remains a major British-Swedish multinational pharmaceutical and biotechnology company with its global headquarters in Cambridge, United Kingdom.